[Form 4] Tango Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Third Rock Ventures-related entities reported a sale of Tango Therapeutics (TNGX) shares. On 08/22/2025, Third Rock Ventures IV, L.P. sold 302,194 shares of common stock in multiple transactions at a weighted average price of $7.00–$7.05 per share. After the sale, the reporting person holds 15,456,881 shares, held indirectly through the fund and its GP structure. The filing lists Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC as reporting persons and includes a footnote clarifying the weighted-average price range and the entities' disclaimers of beneficial ownership except to the extent of pecuniary interest.

Positive

• None.

Negative

• Reported sale of 302,194 common shares on 08/22/2025, reducing holdings to 15,456,881 shares.
• Sale price range disclosed as weighted average $7.00–$7.05, indicating shares were disposed of below some prior price points (if any).

Insights

Securities Analyst

TL;DR: Insider sale of 302,194 TNGX shares reduces reported holdings to 15.46M; transaction disclosed at $7.00–$7.05 weighted average.

The Form 4 documents a non-derivative disposition by Third Rock Ventures IV, L.P. The report is specific about quantity sold, the price range, and the resulting beneficial ownership. For investors, the filing provides clear transactional data without additional commentary on rationale or planned further sales. The weighted-average price disclosure and offer to provide per-trade details increases transparency.

Corporate Governance Expert

TL;DR: Proper Section 16 disclosure completed by GP and related entities; structure and disclaimers are standard for private fund reporting.

The filing shows compliant reporting by the fund, its GP, and GP LLC with signed certifications. Footnote disclosures about the GP relationships and disclaimer of beneficial ownership are standard and clarify indirect ownership. The form does not provide any admission of beneficial ownership beyond pecuniary interest, consistent with common governance practice for VC/GP structures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Third Rock Ventures IV, L.P.

(Last) (First) (Middle)

C/O THIRD ROCK VENTURES, LLC

201 BROOKLINE AVE, SUITE 1401

(Street)

BOSTON MA 02215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		S		302,194	D	$7(1)	15,456,881	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Third Rock Ventures IV, L.P.

(Last) (First) (Middle)

C/O THIRD ROCK VENTURES, LLC

201 BROOKLINE AVE, SUITE 1401

(Street)

BOSTON MA 02215

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Third Rock Ventures GP IV, L.P.

(Last) (First) (Middle)

201 BROOKLINE AVE, SUITE 1401

(Street)

BOSTON MA 02215

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

TRV GP IV, LLC

(Last) (First) (Middle)

201 BROOKLINE AVE, SUITE 1401

(Street)

BOSTON MA 02215

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

2. These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

	/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P.	08/26/2025
	/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P.	08/26/2025
	/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Third Rock Ventures disclose in the Form 4 for Tango Therapeutics (TNGX)?

The filing reports a disposition of 302,194 shares on 08/22/2025 at a weighted average price of $7.00–$7.05, leaving 15,456,881 shares beneficially owned.

Who filed the Form 4 reporting the TNGX transaction?

The report was filed by Third Rock Ventures IV, L.P. and related entities: Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC.

Was the transaction an acquisition or a disposition?

The transaction was a disposition (sale) of common stock, reported with transaction code "S" on the Form 4.

How is beneficial ownership held after the reported sale?

The filing states the shares are directly held by Third Rock Ventures IV, L.P. and the general partner entities disclaim beneficial ownership except to the extent of any pecuniary interest.

Does the Form 4 provide per-trade prices for the shares sold?

No per-trade prices are listed; the filing provides a weighted average price of $7.00–$7.05 and offers to supply detailed per-trade information upon request.